Currently viewing the tag: "Pfizer"

Monday Morning JETLawg

On June 7, 2010 By JETLaw

In the news…

Scientists use brain scans to determine what makes long-term marriages last.

David Carradine’s widow files wrongful death suit against French production company.

MPAA considers whether to turn its litigious attentions to Ashton Kutcher for pirating a portion of his upcoming movie.

New patent [...]

Continue Reading

The Cost of Kickbacks

On January 26, 2010 By JETLaw

To the drug companies that are awarding kickbacks for prescribing or otherwise recommending their drugs, I have two words: stop it!

I respect the time, effort, and money that pharmaceutical companies devote to drug research and development, and advertising the drugs that are ultimately developed is an inevitable part of the research and development [...]

Continue Reading

Monday Morning JetLawg

On December 6, 2009 By JETLaw

In the news . . .

Sprint providing law enforcement with subscribers GPS information.

Is Wikipedia becoming an oligarchy?

Disabled mayor prepared to bring ADA claim against Disney World for treatment over four-wheeled iBOT at Magic Kingdom. German tourist arrested at same park for making security [...]

Continue Reading

Monday Morning JetLawg

On November 22, 2009 By JETLaw

In the news . . .

Wired writer tries to find out if it’s possible to disappear in the digital world.

England’s proposed new copyright laws are extremely controversial.

Insurance company takes away Canadian woman’s long-term sick leave benefit after Facebook photos indicate she wasn’t suffering from depression.

Sony [...]

Continue Reading

Marketing Has a High Price Tag for Pfizer

On September 9, 2009 By JETLaw

Pfizer offered a major “mea culpa” last week when it agreed to pay $2.3 billion in fines for the “largest combined federal and state health care fraud settlement in the history of the Department of Justice.” The pharmaceutical company has ended up in this less than esteemed position as a result of its [...]

Continue Reading

Pfizer, Inc., the world’s largest research-based pharmaceutical company, announced on October 1 that it plans to discontinue research and development in the areas of heart disease, cholesterol, obesity and bone health. The company predicated its decision on the scheduled 2011 expiration of the company’s patent for its bestselling, cholesterol-reducing drug, Lipitor. Research and [...]

Continue Reading